Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
12
THNR Quote, Financials, Valuation and Earnings
Last price:
$22.60
Seasonality move
:
--
Day range:
$23.12 - $23.14
52-week range:
$22.00 - $28.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.3K
Avg. volume:
1.7K
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | -- | -- | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$23.12 | -- | -- | -- | $0.00 | 0% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$24.33 | -- | -- | -- | $0.24 | 0.98% | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$17.33 | -- | -- | -- | $0.00 | 0% | -- |
|
HART
NYLI Healthy Hearts ETF
|
$31.18 | -- | -- | -- | $0.06 | 1.19% | -- |
|
SYNB
Putnam BioRevolution ETF
|
$30.05 | -- | -- | -- | $0.21 | 0.71% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.890 | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.528 | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | 0.784 | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | 1.222 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
HART
NYLI Healthy Hearts ETF
|
-- | -- | -- | -- | -- | -- |
|
SYNB
Putnam BioRevolution ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About THNR or BBC?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is THNR or BBC More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.043, suggesting its more volatile than the S&P 500 by 4.293%.
-
Which is a Better Dividend Stock THNR or BBC?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.98% to investors and pays a quarterly dividend of $0.24 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or BBC?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns THNR or EKG?
First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -
What do Analysts Say About THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 -
Is THNR or EKG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- --
-
Which has Higher Returns THNR or HART?
NYLI Healthy Hearts ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat NYLI Healthy Hearts ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- HARTNYLI Healthy Hearts ETF-- -- -- -
What do Analysts Say About THNR or HART?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand NYLI Healthy Hearts ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than NYLI Healthy Hearts ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than NYLI Healthy Hearts ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 HARTNYLI Healthy Hearts ETF0 0 0 -
Is THNR or HART More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NYLI Healthy Hearts ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or HART?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NYLI Healthy Hearts ETF offers a yield of 1.19% to investors and pays a quarterly dividend of $0.06 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. NYLI Healthy Hearts ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or HART?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than NYLI Healthy Hearts ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than NYLI Healthy Hearts ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while NYLI Healthy Hearts ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for NYLI Healthy Hearts ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- HARTNYLI Healthy Hearts ETF-- -- -- --
-
Which has Higher Returns THNR or SYNB?
Putnam BioRevolution ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Putnam BioRevolution ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- SYNBPutnam BioRevolution ETF-- -- -- -
What do Analysts Say About THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Putnam BioRevolution ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Putnam BioRevolution ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Putnam BioRevolution ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 SYNBPutnam BioRevolution ETF0 0 0 -
Is THNR or SYNB More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Putnam BioRevolution ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Putnam BioRevolution ETF offers a yield of 0.71% to investors and pays a quarterly dividend of $0.21 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Putnam BioRevolution ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or SYNB?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Putnam BioRevolution ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Putnam BioRevolution ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Putnam BioRevolution ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Putnam BioRevolution ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- SYNBPutnam BioRevolution ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
